Claims for Patent: 8,247,415

Summary for Patent: 8,247,415

Title:	Hydroxymethyl pyrrolidines as .beta.3 adrenergic receptor agonists
Abstract:	The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of .beta.3-adrenoceptor. ##STR00001##
Inventor(s):	Berger; Richard (Princeton, NJ), Chang; Lehua (Ramsey, NJ), Edmondson; Scott D. (Clark, NJ), Goble; Stephen D. (Edison, NJ), Ha; Sookhee Nicole (Warren, NJ), Kar; Nam Fung (Brooklyn, NY), Kopka; Ihor E. (Hampton, NJ), Li; Bing (Towaco, NJ), Morriello; Gregori J. (Randolph, NJ), Moyes; Chris R. (Westfield, NJ), Shen; Dong-Ming (Edison, NJ), Wang; Liping (Dayton, NJ), Zhu; Cheng (Edison, NJ)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	12/417,239
Patent Claims:	1. A compound of Formula Ia, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof: ##STR00542## wherein n is 0, 1 or 2; Y is selected from the group consisting of methylene, --CH(CH.sub.3)-- and a bond; Z is selected from the group consisting of ##STR00543## R.sup.3 is selected from the group consisting of: (1) methyl, (2) oxo, and (3) --NH.sub.2. 2. The compound of claim 1 wherein Z is selected from the group consisting of: ##STR00544## 3. The compound of claim 2, wherein n is 1; Y is a bond; Z is ##STR00545## R.sup.3 is oxo. 4. A compound of claim 1 selected from the group consisting of: ##STR00546## or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable stereoisomer thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof. 5. A compound of claim 4, wherein the compound is selected from the group consisting of: ##STR00547## or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable stereoisomer thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof. 6. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 7. A method for the treatment or prevention of a disease or disorder selected from the group consisting of (1) overactive bladder, (2) urinary incontinence, (3) urge urinary incontinence, and (4) urinary urgency, wherein said method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1. 8. A method for the treatment or prevention of a disease or disorder selected from the group consisting of (1) overactive bladder, (2) urinary incontinence, (3) urge urinary incontinence, and (4) urinary urgency, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 and a second active agent. 9. The method of claim 8, wherein the second active agent is a muscarinic receptor antagonist. 10. The compound of claim 1 having the following chemical structure: ##STR00548## or a pharmaceutically acceptable salt thereof. 11. The compound of claim 1 having the following chemical structure: ##STR00549## or a pharmaceutically acceptable salt thereof. 12. A compound having the following chemical structure: ##STR00550## 13. A compound having the following chemical structure: ##STR00551## 14. A pharmaceutical composition comprising a compound of claim 1, a second active agent and a pharmaceutically acceptable carrier. 15. The pharmaceutical composition of claim 14, wherein the second active agent is a muscarinic receptor antagonist. 16. The pharmaceutical composition of claim 15, wherein the second active agent is a tolterodine.